Literature DB >> 28631736

Haematological cancer: Staging and restaging patients with lymphoma - a better approach?

Vijaya R Bhatt1, James O Armitage1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28631736     DOI： 10.1038/nrclinonc.2017.81

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

Review 1.  Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Blood       Date:  2016-04-14       Impact factor: 22.113

2.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

3.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

Authors:  K Spaepen; S Stroobants; P Dupont; S Van Steenweghen; J Thomas; P Vandenberghe; L Vanuytsel; G Bormans; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

5.  Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?

Authors:  M J Reinhardt; C Herkel; C Altehoefer; J Finke; E Moser
Journal:  Ann Oncol       Date:  2005-06-09       Impact factor: 32.976

Review 6.  Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

Authors:  Bruce D Cheson; Stephen Ansell; Larry Schwartz; Leo I Gordon; Ranjana Advani; Heather A Jacene; Axel Hoos; Sally F Barrington; Philippe Armand
Journal:  Blood       Date:  2016-08-29       Impact factor: 22.113

7.  Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma.

Authors:  Bouthaina S Dabaja; Jack Phan; Osama Mawlawi; L Jeffrey Medeiros; Carol Etzel; Fu-Wen Liang; Donald Podoloff; Yasuhiro Oki; Fredrick B Hagemeister; Hubert Chuang; Luis E Fayad; Jason Robert Westin; Ferial Shihadeh; Pamela K Allen; Christine F Wogan; Maria A Rodriguez
Journal:  Leuk Lymphoma       Date:  2013-05-07

8.  In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.

Authors:  Martin Hutchings; Lale Kostakoglu; Jan Maciej Zaucha; Bogdan Malkowski; Alberto Biggi; Iwona Danielewicz; Annika Loft; Lena Specht; Dominick Lamonica; Myron S Czuczman; Christina Nanni; Pier Luigi Zinzani; Louis Diehl; Richard Stern; Morton Coleman
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

Review 9.  International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Authors:  A Younes; P Hilden; B Coiffier; A Hagenbeek; G Salles; W Wilson; J F Seymour; K Kelly; J Gribben; M Pfreunschuh; F Morschhauser; H Schoder; A D Zelenetz; J Rademaker; R Advani; N Valente; C Fortpied; T E Witzig; L H Sehn; A Engert; R I Fisher; P-L Zinzani; M Federico; M Hutchings; C Bollard; M Trneny; Y A Elsayed; K Tobinai; J S Abramson; N Fowler; A Goy; M Smith; S Ansell; J Kuruvilla; M Dreyling; C Thieblemont; R F Little; I Aurer; M H J Van Oers; K Takeshita; A Gopal; S Rule; S de Vos; I Kloos; M S Kaminski; M Meignan; L H Schwartz; J P Leonard; S J Schuster; V E Seshan
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

10.  Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Authors:  Peter Johnson; Massimo Federico; Amy Kirkwood; Alexander Fosså; Leanne Berkahn; Angelo Carella; Francesco d'Amore; Gunilla Enblad; Antonella Franceschetto; Michael Fulham; Stefano Luminari; Michael O'Doherty; Pip Patrick; Thomas Roberts; Gamal Sidra; Lindsey Stevens; Paul Smith; Judith Trotman; Zaid Viney; John Radford; Sally Barrington
Journal:  N Engl J Med       Date:  2016-06-23       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.